Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

IL-33 augments virus-specific memory T Cell inflation and potentiates the efficacy of an attenuated cytomegalovirus-based vaccinea

McLaren, James ORCID: https://orcid.org/0000-0002-7021-5934, Clement, Mathew ORCID: https://orcid.org/0000-0002-9280-5281, Marsden, Morgan, Miners, Kelly L., Llewellyn-Lacey, Sian, Grant, Emma J., Rubina, Anzelika, Gimeno Brias, Silvia, Gostick, Emma, Stacey, Maria A., Orr, Selinda J., Stanton, Richard J. ORCID: https://orcid.org/0000-0002-6799-1182, Ladell, Kristin ORCID: https://orcid.org/0000-0002-9856-2938, Price, David A. ORCID: https://orcid.org/0000-0001-9416-2737 and Humphreys, Ian R. ORCID: https://orcid.org/0000-0002-9512-5337 2019. IL-33 augments virus-specific memory T Cell inflation and potentiates the efficacy of an attenuated cytomegalovirus-based vaccinea. Journal of Immunology 202 (3) , pp. 943-955. 10.4049/jimmunol.1701757

[thumbnail of jimmunol.1701757.full.pdf]
Preview
PDF - Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview

Abstract

Candidate vaccines designed to generate T cell–based immunity are typically vectored by nonpersistent viruses, which largely fail to elicit durable effector memory T cell responses. This limitation can be overcome using recombinant strains of CMV. Proof-of-principle studies have demonstrated the potential benefits of this approach, most notably in the SIV model, but safety concerns require the development of nonreplicating alternatives with comparable immunogenicity. In this study, we show that IL-33 promotes the accumulation and recall kinetics of circulating and tissue-resident memory T cells in mice infected with murine CMV. Using a replication-deficient murine CMV vector, we further show that exogenous IL-33 boosts vaccine-induced memory T cell responses, which protect against subsequent heterologous viral challenge. These data suggest that IL-33 could serve as a useful adjuvant to improve the efficacy of vaccines based on attenuated derivatives of CMV.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Additional Information: This article is distributed under the terms of the CC BY 4.0 Unported license.
Publisher: American Association of Immunologists
ISSN: 0022-1767
Funders: Wellcome Trust
Date of First Compliant Deposit: 18 January 2019
Date of Acceptance: 21 November 2018
Last Modified: 11 Oct 2023 21:38
URI: https://orca.cardiff.ac.uk/id/eprint/118404

Citation Data

Cited 19 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics